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Background: Lethal-7 (let-7) is a tumour suppressor miRNA which acts by down-regulating several oncogenes includ-
ing KRAS. A single-nucleotide polymorphism (rs61764370, T > G base substitution) in the let-7 complementary site 6
(LCS-6) of KRAS mRNA has been shown to predict prognosis in early-stage colorectal cancer (CRC) and beneﬁt from
anti-epidermal growth factor receptor monoclonal antibodies in metastatic CRC.
Patients and methods: We analysed rs61764370 in EXPERT-C, a randomised phase II trial of neoadjuvant CAPOX
followed by chemoradiotherapy, surgery and adjuvant CAPOX plus or minus cetuximab in locally advanced rectal cancer.
DNAwas isolated from formalin-ﬁxed parafﬁn-embedded tumour tissue and genotyped using a PCR-based commercially
available assay. Kaplan–Meier method and Cox regression analysis were used to calculate survival estimates and
compare treatment arms.
Results: A total of 155/164 (94.5%) patients were successfully analysed, of whom 123 (79.4%) and 32 (20.6%) had the
LCS-6 TT and LCS-6 TG genotype, respectively. Carriers of the G allele were found to have a statistically signiﬁcantly
higher rate of complete response (CR) after neoadjuvant therapy (28.1% versus 10.6%; P = 0.020) and a trend for better
5-year progression-free survival (PFS) [77.4% versus 64.5%: hazard ratio (HR) 0.56; P = 0.152] and overall survival (OS)
rates (80.3% versus 71.9%: HR 0.59; P = 0.234). Both CR and survival outcomes were independent of the use of cetuxi-
mab. The negative prognostic effect associated with KRAS mutation appeared to be stronger in patients with the LCS-6
TT genotype (HR PFS 1.70, P = 0.078; HR OS 1.79, P = 0.082) compared with those with the LCS-6 TG genotype (HR
PFS 1.33, P = 0.713; HR OS 1.01, P = 0.995).
Conclusion: This analysis suggests that rs61764370 may be a biomarker of response to neoadjuvant treatment and an
indicator of favourable outcome in locally advanced rectal cancer possibly by mitigating the poor prognosis of KRAS
mutation. In this setting, however, this polymorphism does not appear to predict cetuximab beneﬁt.
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introduction
miRNAs are short, non-coding, sequences of nucleotides which
regulate gene expression by binding to complementary sites
in the 30-untranslated region (30UTRs) of target mRNAs [1].
Approximately 2000 miRNAs have been described in humans
so far and mounting evidence suggests that these molecules may
play an important role in the mechanisms of cell proliferation,
differentiation, carcinogenesis, tumour progression and response
to treatment [1–4].
The lethal-7 (let-7) family members are among the most stud-
ied miRNAs in human malignancies. They generally act as tum-
our suppressors by down-regulating oncogenes involved in the
control of the cell cycle or intracellular signalling cascades [5].
KRAS is an established target of let-7, several complementary
sites for this miRNA being described in the 30UTR of the mRNA
[6]. A single-nucleotide polymorphism (SNP) (rs61764370, T >G
base substitution) in the let-7 complementary site 6 (LCS-6) has
been reported in ∼18% of Caucasians with colorectal cancer
(CRC) [7]. This polymorphism modiﬁes the let-7 binding afﬁnity
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for KRAS ultimately leading to reduced KRAS inhibition and
increased tumour proliferation [8].
A number of studies investigated the role of the LCS-6 variant
either as a prognostic marker in early CRC or as a predictive
marker for anti-epidermal growth factor receptor (EGFR) therap-
ies in metastatic CRC [7, 9–16]. The results have been largely in-
consistent possibly due to a signiﬁcant inter-study heterogeneity
with regard to sample size, patient characteristics and treatment.
Notably, although the prognostic relevance of KRAS mutation
appears greater in rectal cancer compared with colon cancer [17,
18], studies addressing the role of this polymorphism in a homo-
geneous series of rectal cancer patients are lacking.
We analysed the LCS-6 variant in EXPERT-C, an international,
multicentre, randomised phase II trial investigating the addition
of cetuximab to a sequential treatment with neoadjuvant capecita-
bine and oxaliplatin (CAPOX) followed by chemo-radiotherapy
(CRT), surgery and adjuvant CAPOX in patients with locally
advanced rectal cancer (LARC) [19].
methods
The EXPERT-C trial included LARC patients with at least one of the follow-
ing magnetic resonance imaging high-risk features: tumour within 1 mm of
mesorectal fascia, T3 distal (at/below levators) tumour, T3c/T3d tumour
(extramural extension ≥5 mm), T4 tumour, extramural vascular invasion
[19]. Patients were randomised to four cycles of neoadjuvant CAPOX fol-
lowed by capecitabine-based CRT, surgery and four cycles of adjuvant
CAPOX or the same treatment plus cetuximab (Figure 1) [19]. All patients
provided written informed consent.
molecular analysis
DNAwas isolated from formalin-ﬁxed parafﬁn-embedded tumour tissue from
pre-treatment biopsies and/or resection samples using the QIAamp DNA
FFPE Tissue Kit (Qiagen, Hilden, Germany). Samples were genotyped using
custom Taqman assay (Life Technologies, Carlsbad, CA) (probes available
upon request). Cases, negative controls and duplicate samples were processed
in a random order. Both inter- and intra-plate duplicates (10% of the samples)
were 100% concordant. Analysis of KRAS (exons 2–4), NRAS (exons 2–4) and
BRAF (codon 600) was carried out as previously described [19, 20].
statistical considerations
The primary end point of the EXPERT-C trial was complete response (CR)
in patients with KRAS/BRAF wild-type tumours. Hardy–Weinberg equilib-
rium was assessed using the χ2 test. The Kaplan–Meier method was used to
calculate survival estimates and comparison between the treatment arms was
carried out using a log-rank analysis. Hazard ratios (HRs) and 95% conﬁ-
dence intervals (CIs) were obtained from Cox regression. An interaction
term between treatment arm and LCS-6 genotype was included in the Cox
regression. Multivariate Cox regression was used to assess whether a
signiﬁcant interaction remained signiﬁcant after addition of prognostic vari-
ables. Variables were included in the multivariate model using forward selec-
tion if P value <0.1.
results
One hundred and sixty-four patients were enrolled into the
EXPERT-C trial. Of these, 155 (94.5%) had tumour tissue avail-
able for LCS-6 genotyping, 77 in the CAPOX-C arm and 78 in
the CAPOX arm. Table 1 shows patient characteristics. No sig-
niﬁcant differences, overall and by treatment arm, were observed
compared with the original EXPERT-C trial population (data
not shown).
Genotyping was successful in all assessable patients. One
hundred and twenty-three patients (79.4%) had the LCS-6 TT
genotype (CAPOX = 65; CAPOX-C = 58) while 32 (20.6%) had
the LCS-6 TG genotype (CAPOX= 13; CAPOX-C = 19). Hardy–
Weinberg equilibrium was observed (P = 0.152). There was no as-
sociation between the LCS-6 genotype and baseline characteristics
including demographics and clinico-pathological features. More
patients in the LCS-6 variant group had tumours harbouring
KRAS (54.8% versus 41.5%), KRAS/NRAS (58.1% versus 45.8%)
and BRAF mutation (6.5% versus 1.7%). These differences how-
ever were not statistically signiﬁcant.
After neoadjuvant treatment, 13/123 patients (10.6%) in the
LCS-6 TT genotype group achieved CR compared with 9/32
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Figure 1. EXPERT-C trial design. R, randomisation; CAPOX, capecitabine
and oxaliplatin; C, cetuximab; Cape, capecitabine; RT, radiotherapy.
Table 1. Baseline patient characteristics by LCS6 genotype
LCS6 TT
genotype
(N = 123)
LCS6 TG
genotype
(N = 32)
P
value
n % n %
Gender
Male 75 61.0 19 59.4 0.869
Female 48 39.0 13 40.6
Age [mean (SD) and
range]
60 (10.5) 38–74 61 (11.1) 28–79 0.084
WHO performance status
0 57 46.3 16 50.0 0.712
≥1 66 53.7 16 50.0
MRI-defined high-risk features
T3c–T3d 81 65.9 17 53.1 0.183
T4 29 23.6 10 31/3 0.373
CRM involved/at
risk
73 59.3 16 50.0 0.341
EMVI positive 90 73.2 24 75.0 0.834
Low-lying tumour 87 70.7 27 84.4 0.119
Mutations
KRAS 49 41.5 17 54.8 0.184
NRAS 5 4.3 1 3.2 1.00
KRAS/NRAS 54 45.8 18 58.1 0.223
BRAF 2 1.7 2 6.5 0.191
PIK3CA 8 6.8 2 6.5 1.00
TP53 69 52.6 15 50.0 0.797
SD, standard deviation; WHO, World Health Organisation: MRI,
magnetic resonance imaging; CRM, circumferential resection margin;
EMVI, extramural venous invasion.
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(28.1%) in the LCS-6 TG genotype group (P = 0.020, adjusted
P = 0.044). In both groups, no signiﬁcant differences in CR rate
were observed with or without cetuximab (10.3% versus 10.8%,
P = 1.00 and 31.6% versus 23.1%, P = 0.704, respectively,
treatment*LCS-6 P interaction = 0.638) or in KRAS wild-type
versus KRAS mutant tumours (10.1% versus 8.2%, P = 1.00 and
21.4% and 29.4%, P = 0.698, KRAS*LCS-6 P interaction = 0.534).
After a median follow-up of 64.9 months (95% CI 62.8–67.2),
numerically higher 5-year progression-free survival (PFS) [77.4%
versus 64.5%, HR 0.56 (95% CI 0.25–1.24), P = 0.152] and 5-year
overall survival (OS) rates [80.3% versus 71.9%, HR 0.59 (95% CI
0.25–1.41), P = 0.234] favouring the LCS-6 TG genotype group
were observed in the entire population (Figure 2). In cetuximab-
treated patients, survival outcomes were independent of the geno-
type group. The 5-year PFS and OS rates in patients with the
LCS-6 TT genotype treated in the CAPOX-C arm were 66.7%
and 77.0%, respectively, compared with 62.7% and 67.4% in
patients with the same genotype treated in the CAPOX arm
[HR PFS 0.78 (95% CI 0.43–1.42) P = 0.420; HR OS 0.62 (95%
CI 0.32–1.21) P = 0.159]. The 5-year PFS and OS rates in
patients with the LCS-6 TG genotype treated in the CAPOX-C
arm were 78.9% and 83.9%, respectively, compared with 75.0%
and 75.0% in patients with the same genotype treated in the
CAPOX arm [HR PFS 0.80 (95% CI 0.19–3.70) P = 0.804; HR
OS 0.65 (95% CI 0.13–3.22) P = 0.597] (Figure 3). No inter-
action between cetuximab and LCS-6 genotype was observed for
both PFS (P = 0.937) and OS (P = 0.973).
Thirty-one patients (25.2%) in the LCS-6 TT genotype group
and 5 patients (15.6%) in the LCS-6 TG genotype group had
tumour recurrence. The most common sites of disease recurrence
were liver (41.7%), lung (44.4%), peritoneum (19.4%) and lymph
nodes (16.7%). The rate of liver relapse was different between the
two groups: 15 patients out of 123 (12.2%) in the LCS-6 TT geno-
type group were diagnosed with liver metastases (accounting for
48.4% of all relapsed patients in this group) compared with 0/32
patients with the LCS-6 TG genotype (P = 0.038).
When the survival outcomes were analysed by KRAS status,
the prognostic trend associated with the LCS-6 TG genotype
appeared to be stronger in patients with KRAS mutant tumours
[5-year PFS 75.0% versus 54.5%, HR 0.49 (95% CI 0.17–1.43),
P = 0.192; 5-year OS 81.3% versus 62.4%, HR 0.42 (95% CI
0.12–1.41), P = 0.158] compared with patients with KRAS wild-
type tumours [5-year PFS 78.6% versus 69.0%, HR 0.59 (95% CI
0.17–1.96), P = 0.385; 5-year OS 78.6% versus 76.5%, HR 0.78
(95% CI 0.23–2.69), P = 0.703] (Figure 4). KRAS mutation was
found to have a negative prognostic impact in patients with the
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Figure 2. Progression-free survival (A) and overall survival (B) by LCS6 genotype in the entire study population. HR, hazard ratio; CI, conﬁdence interval.
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Figure 3. Progression-free survival (A) and overall survival (B) by LCS6 genotype and treatment arm. a, patients with LCS6 TT genotype treated in the
CAPOX arm; b, patients with LCS6 TT genotype treated in the CAPOX-C arm; c, patients with LCS6 TG genotype treated in the CAPOX arm; d, patients with
LCS6 TG genotype treated in the CAPOX-C arm. HR, hazard ratio; CI, conﬁdence interval.
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LCS-6 TT genotype [HR PFS: 1.70 (95% CI 0.94–3.08),
P = 0.078; HR OS: 1.79 (95% CI 0.93–3.44), P = 0.082] but
not in those with the LCS-6 TG genotype [HR PFS: 1.33 (95%
CI 0.30–5.92), P = 0.713; HR OS: 1.01 (95% CI 0.20–4.99),
P = 0.995]. However, possibly due to the small numbers, the
interaction test did not show any interaction between the LCS-6
genotype and KRAS status for both PFS (P = 0.765) and OS
(P = 0.473). Similar results were observed in the analysis by RAS
(i.e. KRAS and NRAS) or RAS/BRAF status (data not shown).
discussion
In this retrospective analysis of the EXPERT-C trial, we showed
that rs61764370 was not a predictive factor for cetuximab in
LARC. However, this polymorphic variant was associated with a
higher rate of CR to neoadjuvant therapy and a trend towards
better survival outcomes, especially in the subgroup of patients
with KRASmutant tumours.
To our knowledge, this is the ﬁrst report on the role of the
LCS-6 variant in a homogeneous series of LARC. Previous
studies investigating this SNP were either restricted to patients
with colon cancer or conducted in unselected CRC populations
[7, 9–16]. However, differences exist between colon and rectal
cancers with regards to tumour biology and treatment approach
including frequency of microsatellite instability and BRAF mu-
tation, prognostic relevance of KRAS mutation, miRNA expres-
sion proﬁle and routine use of radiotherapy in LARC [21].
We assessed the role of the LCS-6 variant with an aim to val-
idate two intriguing hypotheses generated by previous analyses.
The ﬁrst hypothesis is that this variant may predict beneﬁt from
anti-EGFR agents and reﬁne the selection of metastatic CRC
patients who are candidate for these therapies [16]. The second
hypothesis is that the LCS-6 G allele may be a favourable prog-
nostic factor in the non-metastatic setting and be used in the de-
cision-making process regarding adjuvant treatment [14]. To
this end, we used a prospective series of LARC patients who
were treated with systemic chemotherapy followed by CRT plus
or minus cetuximab in a randomised phase II trial [19].
The incidence of the LCS-6 variant in our population was in
line with what has been previously reported [7, 16]. We could
not ﬁnd an association between this polymorphism and patient
characteristics. Of note, our study is the ﬁrst to include data on
RAS (KRAS and NRAS, exon 2–4) mutation in this setting and,
although a higher incidence of RAS and BRAF mutation was
observed in carriers of the G allele, this was not statistically
signiﬁcant.
The main and novel ﬁnding of our analysis is that patients
with the LCS-6 TG genotype had a higher rate of CR after pre-
operative treatment. This translated into numerically higher, but
not statistically signiﬁcantly improved, survival outcomes pos-
sibly due to the relatively small sample size, the low number of
events and the limited statistical power of the study. Of note, the
better prognosis of the LCS-6 variant group was independent of
cetuximab. These results do not conﬁrm, at least in the setting
of LARC, an association between LCS-6 genotype and beneﬁt
from anti-EGFR agents. However, they suggest that the LCS-6
variant may act as a prognostic factor possibly by modulating
the cytotoxic effects of CRT. In support of this contention, pre-
clinical studies showed that the expression of let-7 changed in
response to irradiation. Moreover, manipulating the expression
of speciﬁc let-7 miRNAs was associated with radiosensitivity
(i.e. when increasing let-7a or let-7b levels) or radio-resistance
(i.e. when reducing let-7 g levels) in RAS mutant pancreatic and
lung cancer cell lines [22–24]. We acknowledge that our results
are hypothesis-generating. A better understanding of the rela-
tionship between let-7 and radiotherapy as well as validation of
our ﬁndings in independent series is certainly needed. Also, it
should be noted that both treatment arms of the EXPERT-C
trial were investigational in that oxaliplatin-based chemotherapy
was administered before CRT. Given the absence of a control
group treated with standard ﬂuoropyrimidine-based CRT only,
we cannot rule out that the improved outcome of the G carriers
could be secondary to increased sensitivity to induction systemic
chemotherapy. In this regard, it has been previously shown that,
in tumour cells harbouring the LCS-6 variant allele, the func-
tional effects of chemotherapy (as measured by KRAS expres-
sion) were different among cytotoxic agents [16].
In subgroup analyses by KRAS status, we observed that the
favourable prognostic effect of the LCS-6 variant was limited to
patients with KRAS mutant tumours. Interestingly, this ﬁnding
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Figure 4. Progression-free survival (A) and overall survival (B) by LCS6 genotype and KRAS mutational status. a, patients with LCS6 TT genotype and KRAS
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is consistent with previous reports. In early-stage CRC patients,
Smits et al. showed that G carriers with stage I–II tumours har-
bouring KRAS mutation had a better cancer-speciﬁc survival
compared with KRAS mutant patients with the LCS-6 TT geno-
type [14]. In contrast, patients with KRAS wild-type tumours
had intermediate prognosis regardless of the LCS-6 genotype.
An association between LCS-6 G allele and better prognosis was
also reported in a series of stage III–IV CRC patients enriched
with KRAS mutation [15]. Finally, in a recent analysis of the
NCCTG N0147 trial, the outcome of G carriers with KRAS
mutant stage III colon cancer appeared to be more similar to
that of patients with KRAS wild-type tumours than that of pat-
ients with LCS-6 TT genotype and KRAS mutant tumour [16].
Altogether, these data seem to indicate that the LCS-6 variant
may mitigate the unfavourable prognosis associated with KRAS
mutation in the non-metastatic setting [17, 18]. It has been pro-
posed that this effect may be secondary to induction of cellular
senescence through overexpression of KRAS and increased sig-
nalling through the MAP-K cascade [14]. However, there are
currently no data to conﬁrm this hypothesis and the broad spec-
trum of cancer-related genes which are regulated by let-7 sug-
gests that other mechanisms may be involved.
We recognise the limitations of our study including the retro-
spective design, the small numbers and the analysis of patients
who were treated with investigational therapeutic strategies that
do not reﬂect the current standard of care in this setting.
Moreover, robust biological hypotheses to explain the study
results are lacking. However, this analysis explores for the ﬁrst
time the predictive and prognostic role of the LCS-6 variant in
LARC and provides another piece of the puzzle on the relation-
ship between this SNP and anti-EGFR agents.
The management of LARC is orphan of established biomar-
kers that could lead to optimisation of patient selection, imple-
mentation of molecularly selected treatment approaches and
improved outcomes. So far, studies investigating putative bio-
markers in this setting have been largely unsuccessful. As a
result, conventional clinico-pathological prognostic factors still
remain the only available tools for individual patient risk assess-
ment and treatment decision. Although genetic variations asso-
ciated with SNPs have been reported to inﬂuence cancer risk,
response to treatment and tumour prognosis in a number of
tumour types including CRC, their value in routine practice is
yet to be demonstrated.
Our analysis suggests that, in a Caucasian population, the
rs61764370 SNP may inﬂuence the prognostic relevance of KRAS
mutation which has been increasingly reported as a marker of re-
sistance to CRT in LARC and poor prognosis in distal colon
cancer and rectal cancer [17, 18]. If our ﬁndings are conﬁrmed,
testing for KRAS and rs61764370 could potentially provide useful
data for patient stratiﬁcation in clinical trials of (neo)adjuvant
treatment of LARC. Further studies to elucidate the mechanisms
whereby this SNP may increase tumour (chemo)radiosensiti-
vity and mitigate the unfavourable prognosis of KRAS mutant
tumours are warranted.
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Cetuximab, docetaxel, and cisplatin as ﬁrst-line
treatment in patients with recurrent or metastatic head
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Background: Cetuximab in combination with platinum and 5-ﬂuorouracil is the standard of care in the ﬁrst-line treatment
of patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). Cetuximab and taxane combi-
nations have shown promising activity. This study evaluated the efﬁcacy and safety of four cycles of docetaxel associated
with cisplatin and cetuximab (TPEx), followed by maintenance with cetuximab every 2 weeks.
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